Clovis Oncology Company Profile (NASDAQ:CLVS)

About Clovis Oncology (NASDAQ:CLVS)

Clovis Oncology logoClovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company's product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer. Lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors (VEGFR) 1-3, platelet-derived growth factor receptors (PDGFR) alpha and beta and fibroblast growth factor receptors (FGFR) 1-3. Rociletinib is an oral mutant-selective inhibitor of epidermal growth factor receptor (EGFR).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:CLVS
  • CUSIP: 18946410
  • Web: www.clovisoncology.com
Capitalization:
  • Market Cap: $3.97487 billion
  • Outstanding Shares: 48,879,000
Average Prices:
  • 50 Day Moving Avg: $77.57
  • 200 Day Moving Avg: $71.40
  • 52 Week Range: $25.81 - $99.45
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -31.74
  • P/E Growth: 0.13
Sales & Book Value:
  • Annual Revenue: $21.74 million
  • Price / Sales: 176.99
  • Book Value: $7.04 per share
  • Price / Book: 11.18
Profitability:
  • EBITDA: ($242,160,000.00)
  • Return on Equity: -177.30%
  • Return on Assets: -47.13%
Debt:
  • Debt-to-Equity Ratio: 0.82%
  • Current Ratio: 3.26%
  • Quick Ratio: 3.23%
Misc:
  • Average Volume: 1.61 million shs.
  • Beta: 1.56
  • Short Ratio: 4.95
 

Frequently Asked Questions for Clovis Oncology (NASDAQ:CLVS)

What is Clovis Oncology's stock symbol?

Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS."

How were Clovis Oncology's earnings last quarter?

Clovis Oncology, Inc. (NASDAQ:CLVS) released its quarterly earnings data on Wednesday, August, 2nd. The company reported ($1.29) earnings per share for the quarter, missing analysts' consensus estimates of ($1.27) by $0.02. The business had revenue of $14.62 million for the quarter, compared to the consensus estimate of $13.07 million. The business's quarterly revenue was down 32.5% compared to the same quarter last year. During the same period last year, the firm earned ($2.07) earnings per share. View Clovis Oncology's Earnings History.

When will Clovis Oncology make its next earnings announcement?

Clovis Oncology is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for Clovis Oncology.

Where is Clovis Oncology's stock going? Where will Clovis Oncology's stock price be in 2017?

17 analysts have issued 12-month target prices for Clovis Oncology's shares. Their predictions range from $38.00 to $125.00. On average, they expect Clovis Oncology's stock price to reach $85.79 in the next year. View Analyst Ratings for Clovis Oncology.

What are analysts saying about Clovis Oncology stock?

Here are some recent quotes from research analysts about Clovis Oncology stock:

  • 1. According to Zacks Investment Research, "Clovis’ Rubraca registered impressive sales in the second quarter. The FDA’s accelerated approval to ovarian cancer treatment, Rubraca in Dec 2016 was a huge boost for  the company. Rubraca has bright prospects, given the tremendous demand for PARP inhibitors. Clovis is focused on achieving continued approval for the drug. Rubraca is also under review in the EU for a comparable indication. Several studies on Rubraca, targeting different types of ovarian cancer patients, are currently underway. Promising progression-free survival and safety results from the ARIEL3 maintenance study in Jun 2017 are positives. However, with just one approved product in the portfolio, Clovis is heavily dependent on Rubraca for growth, which concerns us. Clovis’ shares have outperformed the industry so far this year. Loss Estimates have narrowed ahead of the Q3 earnings results. The company has a mixed record of earnings surprises in recent quarters." (10/17/2017)
  • 2. Cann analysts commented, "In a presentation on Saturday at the 2017 European Society for Medical Oncology (ESMO) Congress, Clovis Oncology released additional details from the results of the phase III ARIEL3 study of Rucraca. In addition to PFS results, Clovis presented response rate data from an exploratory analysis of investigator-assessed ORR for patients with measurable disease at baseline. These response rate data are consistent with the previously released PFS data." (9/11/2017)
  • 3. Goldman Sachs Group, Inc. (The) analysts commented, "AZN (covered by Keyur Parekh) presented data from a Ph3 SOLO-2 maintenance ovarian cancer trial of Lynparza (PARP inhibitor) on March 14 at the SGO conference, which we believe has implications for CLVS (lead marketed drug Rubraca is also a PARP). CLVS, AZN and TSRO (not covered) all have PARP inhibitors that they are evaluating for use in the maintenance treatment of ovarian cancer." (3/15/2017)
  • 4. Stifel Nicolaus analysts commented, "This price assumes about a 40% market share for rucaparib throughout addressable ovarian cancer (OC). However, in deriving this target, we include sales in the maintenance setting for ovarian cancer with a weighting of 75% (some risk remains to ARIEL3) and note that full weighing of this unapproved usage would suggest a fair value of about $104. Furthermore, inclusion of sales in mCRPC, which we consider highly promising but where large trials are just starting, suggests a fair value for Clovis shares of about $182. We consider most of the ongoing trials for rucaparib to be relatively low risk, but with several other players also competing for each indication we believe a takeout price of about 50% of our best case scenario makes sense." (1/23/2017)

Who are some of Clovis Oncology's key competitors?

Who are Clovis Oncology's key executives?

Clovis Oncology's management team includes the folowing people:

  • M. James E. Barrett Ph.D., Independent Chairman of the Board
  • Patrick J. Mahaffy, President, Chief Executive Officer, Director
  • Daniel W. Muehl, Senior Vice President of Finance, Principal Accounting Officer and Principal Financial Officer
  • Gillian C. Ivers-Read, Executive Vice President - Technical Operations, Chief Regulatory Officer
  • Lindsey Rolfe BSc, MB ChB, MRCP, F, Executive Vice President - Clinical and Pre-Clinical Development and Pharmacovigilance and Chief Medical Officer
  • C. Dale Hooks, Senior Vice President, Chief Commercial Officer
  • Brian G. Atwood, Independent Director
  • James C. Blair Ph.D., Independent Director
  • Keith T. Flaherty M.D., Independent Director
  • Ginger L. Graham, Independent Director

How do I buy Clovis Oncology stock?

Shares of Clovis Oncology can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Clovis Oncology's stock price today?

One share of Clovis Oncology stock can currently be purchased for approximately $78.72.


MarketBeat Community Rating for Clovis Oncology (NASDAQ CLVS)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  339 (Vote Outperform)
Underperform Votes:  267 (Vote Underperform)
Total Votes:  606
MarketBeat's community ratings are surveys of what our community members think about Clovis Oncology and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Clovis Oncology (NASDAQ:CLVS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 7 Hold Ratings, 10 Buy Ratings
Consensus Rating:Buy (Score: 2.59)
Consensus Price Target: $85.79 (8.98% upside)
Consensus Price Target History for Clovis Oncology (NASDAQ:CLVS)
Price Target History for Clovis Oncology (NASDAQ:CLVS)
Analysts' Ratings History for Clovis Oncology (NASDAQ:CLVS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/10/2017Oppenheimer Holdings, Inc.Reiterated RatingHoldN/AView Rating Details
9/18/2017Leerink SwannReiterated RatingBuy$107.00LowView Rating Details
9/14/2017Royal Bank Of CanadaInitiated CoverageSector Perform$81.00LowView Rating Details
9/11/2017CannReiterated RatingHoldLowView Rating Details
8/18/2017J P Morgan Chase & CoReiterated RatingBuyMediumView Rating Details
8/16/2017Evercore ISIInitiated CoverageIn -> In-Line$73.00HighView Rating Details
8/10/2017Morgan StanleyReiterated RatingOverweight$93.00MediumView Rating Details
8/3/2017Bank of America CorporationReiterated RatingBuyLowView Rating Details
7/18/2017Credit Suisse GroupSet Price TargetBuy$107.00LowView Rating Details
7/7/2017GabelliInitiated CoverageBuy$125.00HighView Rating Details
6/22/2017SunTrust Banks, Inc.Reiterated RatingBuyLowView Rating Details
6/20/2017Goldman Sachs Group, Inc. (The)Reiterated RatingNeutral$67.00 -> $90.00HighView Rating Details
6/20/2017Janney Montgomery ScottUpgradeNeutral -> BuyMediumView Rating Details
6/19/2017Stifel NicolausBoost Price TargetBuy$86.00 -> $125.00HighView Rating Details
6/19/2017Chardan CapitalUpgradeSell -> Neutral$36.00 -> $50.00HighView Rating Details
3/28/2017Piper Jaffray CompaniesSet Price TargetBuy$77.00LowView Rating Details
12/21/2016WallachBeth CapitalBoost Price TargetHold$22.00 -> $49.00N/AView Rating Details
8/24/2016MizuhoBoost Price TargetNeutral$15.00 -> $23.00N/AView Rating Details
(Data available from 10/19/2015 forward)

Earnings

Earnings History for Clovis Oncology (NASDAQ:CLVS)
Earnings by Quarter for Clovis Oncology (NASDAQ:CLVS)
Earnings History by Quarter for Clovis Oncology (NASDAQ CLVS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017($1.18)N/AView Earnings Details
8/2/2017Q2 2017($1.27)($1.29)$13.07 million$14.62 millionViewListenView Earnings Details
5/3/2017Q1 2017($1.43)($1.33)$6.04 million$7.05 millionViewListenView Earnings Details
2/22/2017Q416($1.65)($1.83)$0.08 millionViewListenView Earnings Details
11/3/2016Q316($1.95)($1.70)ViewListenView Earnings Details
8/8/2016Q216($2.13)($2.07)ViewListenView Earnings Details
5/5/2016Q116($2.39)($2.17)ViewListenView Earnings Details
2/25/2016Q415($2.39)($2.23)ViewListenView Earnings Details
11/5/2015Q315($2.07)($2.62)ViewListenView Earnings Details
8/6/2015Q215($2.11)($2.10)$1.17 millionViewListenView Earnings Details
5/6/2015Q115($1.78)($1.86)$13.60 millionViewListenView Earnings Details
2/25/2015Q414($1.41)($1.62)ViewListenView Earnings Details
11/6/2014Q314($1.03)($1.17)ViewListenView Earnings Details
8/7/2014Q214($0.93)($1.03)$13.60 millionViewListenView Earnings Details
5/8/2014Q114($0.85)($0.91)$13.60 millionViewListenView Earnings Details
2/27/2014Q4($0.78)($0.92)ViewListenView Earnings Details
10/31/2013Q313($0.68)($0.68)ViewListenView Earnings Details
8/1/2013Q2 2013($0.65)($0.72)ViewListenView Earnings Details
5/7/2013Q1 2013($0.60)($0.60)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Clovis Oncology (NASDAQ:CLVS)
2017 EPS Consensus Estimate: ($4.97)
2018 EPS Consensus Estimate: ($2.67)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($1.53)($1.53)($1.53)
Q2 20173($1.30)($1.18)($1.23)
Q3 20173($1.24)($1.10)($1.15)
Q4 20173($1.12)($1.03)($1.06)
Q1 20181($0.85)($0.85)($0.85)
Q2 20181($0.67)($0.67)($0.67)
Q3 20181($0.64)($0.64)($0.64)
Q4 20181($0.51)($0.51)($0.51)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Clovis Oncology (NASDAQ:CLVS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Clovis Oncology (NASDAQ:CLVS)
Insider Ownership Percentage: 12.50%
Institutional Ownership Percentage: 98.94%
Insider Trades by Quarter for Clovis Oncology (NASDAQ:CLVS)
Institutional Ownership by Quarter for Clovis Oncology (NASDAQ:CLVS)
Insider Trades by Quarter for Clovis Oncology (NASDAQ:CLVS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/16/2017Gillian C Ivers-ReadInsiderSell3,000$84.54$253,620.00View SEC Filing  
9/15/2017Gillian C Ivers-ReadInsiderSell3,000$69.50$208,500.00View SEC Filing  
8/15/2017Gillian C Ivers-ReadInsiderSell3,000$70.05$210,150.00View SEC Filing  
8/4/2017James C BlairDirectorSell18,450$78.61$1,450,354.50View SEC Filing  
7/17/2017Gillian C Ivers-ReadInsiderSell3,000$91.56$274,680.00View SEC Filing  
6/15/2017Gillian C Ivers-ReadInsiderSell3,000$61.82$185,460.00View SEC Filing  
5/15/2017Gillian C Ivers-ReadInsiderSell3,000$47.39$142,170.00View SEC Filing  
4/17/2017Gillian C Ivers-ReadInsiderSell3,000$56.02$168,060.00View SEC Filing  
3/15/2017Gillian C Ivers-ReadInsiderSell3,000$66.99$200,970.00View SEC Filing  
11/2/2015Erle T. MastCFOSell3,000$105.56$316,680.00View SEC Filing  
10/28/2015Lindsey RolfeinsiderSell4,000$98.02$392,080.00View SEC Filing  
10/15/2015Gillian C Ivers-ReadInsiderSell3,000$91.91$275,730.00View SEC Filing  
10/5/2015Lindsey RolfeinsiderSell4,000$93.04$372,160.00View SEC Filing  
10/1/2015Erle T. MastCFOSell3,000$90.22$270,660.00View SEC Filing  
9/18/2015Gillian C Ivers-ReadInsiderSell3,000$112.56$337,680.00View SEC Filing  
9/1/2015Erle T. MastCFOSell3,000$79.51$238,530.00View SEC Filing  
7/1/2015Erle T MastCFOSell3,000$85.70$257,100.00View SEC Filing  
6/1/2015Erle T MastCFOSell3,000$88.78$266,340.00View SEC Filing  
5/15/2015M James BarrettDirectorSell2,424$92.43$224,050.32View SEC Filing  
4/1/2015Erle T MastCFOSell3,000$71.25$213,750.00View SEC Filing  
3/9/2015Erle T MastCFOSell9,000$78.84$709,560.00View SEC Filing  
3/5/2015James C BlairDirectorSell8,528$77.70$662,625.60View SEC Filing  
1/16/2015Steven L HoerterInsiderSell10,000$67.00$670,000.00View SEC Filing  
12/11/2013Erle MastCFOSell50,000$52.78$2,639,000.00View SEC Filing  
12/5/2013Thorlef SpickschenDirectorSell9,000$56.10$504,900.00View SEC Filing  
6/5/2013Andrew R AllenInsiderSell22,594$68.54$1,548,592.76View SEC Filing  
6/4/2013M James BarrettDirectorSell2,483$70.80$175,796.40View SEC Filing  
6/4/2013Parters Vii L P DomainMajor ShareholderSell159,192$64.58$10,280,619.36View SEC Filing  
6/4/2013Steven L HoerterInsiderSell10,000$73.06$730,600.00View SEC Filing  
3/6/2013Parters Vii L P DomainMajor ShareholderSell250,000$24.59$6,147,500.00View SEC Filing  
8/16/2012Edward J MckinleyDirectorBuy9,701$15.50$150,365.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Clovis Oncology (NASDAQ:CLVS)
Latest Headlines for Clovis Oncology (NASDAQ:CLVS)
Source:
DateHeadline
americanbankingnews.com logoZacks: Analysts Anticipate Clovis Oncology, Inc. (CLVS) to Post -$1.16 EPS
www.americanbankingnews.com - October 19 at 8:19 AM
americanbankingnews.com logoInsider Selling: Clovis Oncology, Inc. (CLVS) Insider Sells 3,000 Shares of Stock
www.americanbankingnews.com - October 17 at 10:20 PM
americanbankingnews.com logoHead-To-Head Analysis: Clovis Oncology (CLVS) and Its Rivals
www.americanbankingnews.com - October 16 at 12:08 AM
americanbankingnews.com logoClovis Oncology, Inc. (CLVS) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - October 15 at 10:44 AM
finance.yahoo.com logoClovis (CLVS) Submits sNDA for Ovarian Cancer Drug Rubraca
finance.yahoo.com - October 10 at 6:28 PM
finance.yahoo.com logoClovis Oncology Submits Supplemental New Drug Application for Rucaparib as Maintenance Treatment for Patients with Platinum-Sensitive Recurrent Ovarian Cancer
finance.yahoo.com - October 9 at 5:56 PM
finance.yahoo.com logoClovis Oncology Scores Relative Strength Rating Upgrade
finance.yahoo.com - October 2 at 5:36 PM
americanbankingnews.com logo Analysts Expect Clovis Oncology, Inc. (CLVS) Will Announce Earnings of -$1.17 Per Share
www.americanbankingnews.com - September 30 at 2:22 PM
seekingalpha.com logoClovis: An Attractive M&A Candidate - Seeking Alpha
seekingalpha.com - September 28 at 10:14 PM
finance.yahoo.com logoClovis Oncology, Inc. breached its 50 day moving average in a Bullish Manner : CLVS-US : September 25, 2017
finance.yahoo.com - September 25 at 12:27 PM
americanbankingnews.com logoClovis Oncology, Inc. (CLVS) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - September 20 at 10:46 AM
americanbankingnews.com logoAnalyzing Clovis Oncology (CLVS) and CytomX Therapeutics (CTMX)
www.americanbankingnews.com - September 19 at 6:10 PM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Dimension Therapeutics and Clovis Oncology
finance.yahoo.com - September 19 at 5:17 PM
finance.yahoo.com logoClovis Oncology (CLVS) in Focus: Stock Moves 10.5% Higher
finance.yahoo.com - September 19 at 5:17 PM
americanbankingnews.com logoClovis Oncology, Inc. (CLVS) Rating Reiterated by Leerink Swann
www.americanbankingnews.com - September 19 at 2:32 PM
nasdaq.com logoHealth Care Sector Update for 09/18/2017: CLVS,LLY,ITUS,AEMD - Nasdaq
www.nasdaq.com - September 19 at 3:28 AM
rttnews.com logoClovis Oncology Inc. (CLVS) Has Broken Out Of Today's Range
www.rttnews.com - September 18 at 5:20 PM
finance.yahoo.com logoSo Much PARP Inhibitor Deal Hype, So Little Payoff
finance.yahoo.com - September 18 at 5:20 PM
finance.yahoo.com logoClovis Up 10% On Double Normal Volume
finance.yahoo.com - September 18 at 5:20 PM
feeds.benzinga.com logoClovis Oncology Higher Off Unconfirmed Takeover Chatter
feeds.benzinga.com - September 18 at 12:34 PM
americanbankingnews.com logoClovis Oncology, Inc. (CLVS) Now Covered by Royal Bank Of Canada
www.americanbankingnews.com - September 14 at 6:06 PM
streetinsider.com logoClovis Oncology (CLVS) ARIEL3 Study of Rucaparib Published in The Lancet - StreetInsider.com
www.streetinsider.com - September 13 at 11:32 PM
finance.yahoo.com logoClovis Oncology’s Rucaparib ARIEL3 Study Data Published in The Lancet
finance.yahoo.com - September 13 at 6:31 PM
americanbankingnews.com logo$20.46 Million in Sales Expected for Clovis Oncology, Inc. (CLVS) This Quarter
www.americanbankingnews.com - September 13 at 3:32 AM
finance.yahoo.com logoShould You Keep Your Portfolio Healthy with Biotech ETFs?
finance.yahoo.com - September 12 at 5:57 PM
finance.yahoo.com logoClovis Oncology Inc (CLVS): Is the Pullback a Buying Opportunity?
finance.yahoo.com - September 11 at 5:57 PM
finance.yahoo.com logoA Pill Might Control Pancreatic Cancer, Even If It Doesn't Cure It
finance.yahoo.com - September 11 at 5:57 PM
americanbankingnews.com logoClovis Oncology's (CLVS) Hold Rating Reaffirmed at Oppenheimer Holdings, Inc.
www.americanbankingnews.com - September 11 at 3:50 PM
americanbankingnews.com logoClovis Oncology, Inc. (CLVS) Stock Rating Reaffirmed by Cann
www.americanbankingnews.com - September 11 at 8:10 AM
streetinsider.com logoClovis Oncology (CLVS) Reports Comprehensive Dataset from Successful Phase 3 ARIEL3 Maintenance Treatment ... - StreetInsider.com
www.streetinsider.com - September 8 at 5:42 PM
streetinsider.com logoClovis Oncology (CLVS) Reports Comprehensive Dataset from Successful Phase 3 ARIEL3 Maintenance Treatment ... - StreetInsider.com
www.streetinsider.com - September 8 at 5:42 PM
finance.yahoo.com logoClovis Spikes on Phase 3 Data for Ovarian Cancer Drug- Biotech Movers
finance.yahoo.com - September 8 at 5:42 PM
nasdaq.com logoClovis (CLVS) Down 8.1% Since Earnings Report: Can It Rebound? - Nasdaq
www.nasdaq.com - September 7 at 10:31 PM
businesswire.com logoClovis Oncology Presents Comprehensive Dataset from Successful Phase 3 ARIEL3 Maintenance Treatment Trial of ... - Business Wire (press release)
www.businesswire.com - September 7 at 10:31 PM
finance.yahoo.com logoClovis Oncology Presents Comprehensive Dataset from Successful Phase 3 ARIEL3 Maintenance Treatment Trial of Rucaparib in Advanced Ovarian Cancer at ESMO 2017
finance.yahoo.com - September 7 at 10:31 PM
finance.yahoo.com logoClovis (CLVS) Down 8.1% Since Earnings Report: Can It Rebound?
finance.yahoo.com - September 7 at 5:27 PM
finance.yahoo.com logoWhy Clovis Oncology Fell 7.1% in August
finance.yahoo.com - September 7 at 5:27 PM
finance.yahoo.com logoClovis Oncology to Present Comprehensive Dataset from Successful ARIEL3 Clinical Trial Program at 2017 ESMO Congress
finance.yahoo.com - August 30 at 5:16 PM
finance.yahoo.com logoAfter Gilead's Acquisition Of KITE, Who Gets Gobbled Up Next?
finance.yahoo.com - August 30 at 5:16 PM
nasdaq.com logoHere's Why Clovis Stock Is Up Almost 60% So Far in 2017 - Nasdaq
www.nasdaq.com - August 23 at 5:54 PM
finance.yahoo.com logoHere's Why Clovis Stock Is Up Almost 60% So Far in 2017
finance.yahoo.com - August 23 at 5:54 PM
finance.yahoo.com logoOvarian Cancer Market Still Up For Grabs
finance.yahoo.com - August 18 at 5:21 PM
finance.yahoo.com logoTesaro: Losing It's Edge?
finance.yahoo.com - August 18 at 5:21 PM
americanbankingnews.com logoClovis Oncology's (CLVS) Buy Rating Reiterated at J P Morgan Chase & Co
www.americanbankingnews.com - August 18 at 11:22 AM
americanbankingnews.com logoClovis Oncology, Inc. (CLVS) PT Lowered to $107.00
www.americanbankingnews.com - August 18 at 8:12 AM
finance.yahoo.com logoClovis Oncology, Inc. – Value Analysis (NASDAQ:CLVS) : August 17, 2017
finance.yahoo.com - August 16 at 10:45 PM
americanbankingnews.com logoClovis Oncology, Inc. (CLVS) Now Covered by Analysts at Evercore ISI
www.americanbankingnews.com - August 16 at 6:58 PM
nasdaq.com logoClovis (CLVS) Focuses on Label Expansion, Rubraca Impresses - Nasdaq
www.nasdaq.com - August 16 at 4:02 AM
americanbankingnews.com logoClovis Oncology, Inc. (CLVS) Insider Sells $210,150.00 in Stock
www.americanbankingnews.com - August 15 at 7:38 PM
finance.yahoo.com logoClovis (CLVS) Focuses on Label Expansion, Rubraca Impresses
finance.yahoo.com - August 15 at 5:58 PM

Social

Chart

Clovis Oncology (CLVS) Chart for Thursday, October, 19, 2017

This page was last updated on 10/19/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.